KP-910 by Kaken Pharmaceutical for Peripheral Neuropathic Pain: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KP-910 overview
KP-910 is under development for the treatment of peripheral neuropathic pain.
Kaken Pharmaceutical overview
Kaken Pharmaceutical (Kaken) is a specialty pharmaceutical company that conducts research and development of drugs, agrochemicals and medical equipment. The company offers solutions in the fields of orthopedics, dermatology, immunology, inflammation, allergy, fungal infections and pain relief. Kaken also offers fungicides, rice herbicide, anti-coccidial for chicken and polypeptide antibiotics. The company conducts research in inflammation and immunology, neurological pain relief and fungal infection areas. It markets products through license and distribution agreements with companies in the US, Canada, Taiwan, China, South Korea, Israel and Jordan and operates sales offices in various places in Japan. Kaken is headquartered in Tokyo, Japan.
For a complete picture of KP-910’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#KP910 #Kaken #Pharmaceutical #Peripheral #Neuropathic #Pain #Likelihood #Approval
